PharmaCorp Rx Inc. PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 6.55% | -5.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.55% | -5.00% | |||
| Cost of Revenue | 3.98% | -5.40% | |||
| Gross Profit | 10.60% | -4.35% | |||
| SG&A Expenses | 15.45% | -22.37% | |||
| Depreciation & Amortization | -6.15% | 4.77% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.43% | -11.63% | |||
| Operating Income | -131.02% | 91.81% | |||
| Income Before Tax | -26.04% | 122.22% | |||
| Income Tax Expenses | -282.26% | -102.55% | |||
| Earnings from Continuing Operations | -5.30% | 114.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -379.56% | 36.87% | |||
| Net Income | -72.24% | 112.06% | |||
| EBIT | -131.02% | 91.81% | |||
| EBITDA | -31.94% | 176.41% | |||
| EPS Basic | -80.00% | 111.36% | |||
| Normalized Basic EPS | -150.00% | 111.11% | |||
| EPS Diluted | -75.00% | 109.09% | |||
| Normalized Diluted EPS | -150.00% | 111.11% | |||
| Average Basic Shares Outstanding | 0.00% | 17.09% | |||
| Average Diluted Shares Outstanding | -0.07% | 23.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||